The capacity of cancer cells to undergo epithelial-tomesenchymal transition (EMT) is now considered a hallmark of tumor progression, and it is known that interactions between cancer cells and mesenchymal stem cells (MSCs) of tumor microenvironment may promote this program. Herein, we demonstrate that MSC-conditioned medium (MSC-CM) is a potent inducer of EMT in melanoma cells. The EMT profile acquired by MSC-CM-exposed melanoma cells is characterized by an enhanced level of mesenchymal markers, including TGFβ/TGFβ-receptors system upregulation, by increased invasiveness and uPAR expression, and in vivo tumor growth.
Introduction
Mesenchymal stem cells (MSCs) are multipotent precursor cells able to differentiate into multiple tissue-forming cell lineages [1] that can be expanded in vitro for several passages without losing their self-renewal capacity. MSCs regulate immune and inflammatory responses, and these properties provide therapeutic potential for treating several human diseases. MSCs can also have a reparative effect by producing molecules that affect cell migration, proliferation, and survival. However, several studies approaching the role of MSCs in tumor progression show that MSCs may display either inhibitory or stimulatory effects. A pivotal study by Karnoub et al. reported that, when MSCs were mixed with breast cancer cells before implantation, they enhance breast cancer cell invasion and in vivo metastatic dissemination. Knockdown of the CCL5-CCR5 loop abrogated metastatic response, indicating that this paracrine interaction plays a role in MSC-mediated malignant phenotype [2] . MSCs, actively recruited to tumor environment of breast tumors, induce epithelial-tomesenchymal transition (EMT) of tumor cells thereby stimulating their metastatic dissemination [3] . Moreover, MSCs attracted by colorectal cancer cells promote tumor growth and metastases [4, 5] . On the contrary, MSCs exert potent anti-tumorigenic effects in a model of Kaposi's sarcoma [6] and inhibit the proliferation of K562 and HL60 cells by suppressing WNT signaling [7] . MSCs effect on prostate cancer are also contradictory, in view of tumor growth inhibition and restoration of bone found [8] and contribution to tumor progression reported by Ye H et al. [9] . In light of all these findings, prudence should be taken when MSCs are exploited to treat human malignancies and specific effects on the several cancer histotype must be proved.
Experimental evidences indicate TGFβ as a potent promoter of EMT via activation of canonical Smad and noncanonical pathways [10] [11] [12] . Moreover, many data indicate a regulative role of TGFβ on membrane-associated plasminogen activation system (urokinase-type plasminogen activator, uPA; uPA receptor, uPAR) in endothelial cells [13] and tumor cells [14] . uPA/uPAR system is actually considered the main system involved in tumor invasion and metastasis, as well as in tumor angiogenesis [15] . Also, in addition to its well-known role in tumor progression, uPAR induce EMT of cancer cells [16] and is involved in hypoxia-induced EMT [17] .
Involvement of MSCs in melanoma progression is still not completely understood. Comparing gene expression profile in a series of vertical growth phase, primary cutaneous malignant melanoma that had developed a metastatic disease indicates that EMT program represents a key step in melanoma progression. EMT promotes in tumor cells several properties, such as an elevated resistance to apoptosis, migration, distant metastasis formation, and acquisition of stem-like phenotype [18] .
Understanding MSC/melanoma cell interaction in inducing EMT is required to go further in melanoma progression. This study investigates effects exerted by MSCs on melanoma cells using in vitro and in vivo assays, evaluating the ability of MSCs to promote an EMT program. We found that melanoma cells treated with MSC-conditioned medium express mesenchymal markers and an enhanced in vitro invasiveness and when co-injected with MSCs express higher tumorigenic potential: all properties compatible with EMT program. We demonstrated that TGFβ1 (TGFβ) triggers EMT via uPAR upregulation in melanoma cells exposed to MSCs.
Materials and methods

Cell lines
Mesenchymal stem cells (MSCs) were obtained from bone marrow aspirates of donors which signed informed consent and were expanded according to Laurenzana et al. [19] . The melanoma cell line A375 (MITF wild type, BRAF V600E, NRAS wild type), M14, Hs294T, and Mewo were obtained from American Type Culture Collection (Manassas, VA) and grown in Dulbecco's modified Eagle's medium (DMEM) with 10 % FBS (Euroclone, Milano, Italy). A375-M6 melanoma cells (M6) were isolated in our laboratory from lung metastasis of SCID bg/bg mice i.v. injected with A375 human melanoma cell lines. SSM2c [20] melanoma cells were available in our laboratory. M21 melanoma cells were kindly provided by Dr. Antony Montgomery (The Scripps Research Institute, La Jolla, CA).
Preparation of conditioned medium by MSC
Conditioned media (MSC-CM) from semiconfluent MSCs were prepared as described in Laurenzana [19] . In some experiments, CM was prepared using MSCs pretreated with small interfering RNA (siRNA) targeting human TGFβ1 and negative control constructs obtained from Riboxx Life Sciences/Euroclone, Milano, Italy (IBONI siRNA-pool,). siRNA constructs were incorporated into RiboxxFECT transfection reagent according to the manufacturer's instructions. Moreover, to target TGFβ in MSC-CM, we used a TGFβRIII antagonist peptide developed by Digna Biotech (Pamplona, Spain) named p17, derived from phage display library technology [21] , at the final concentration of 100 μg/ml [22] .
Evaluation of EMT markers by Western blot analysis, qPCR, confocal microscopy
To evaluate EMT markers, we performed real time PCR, Western blot analysis, and confocal microscopy taking into consideration the specificity of antibodies existing.
Aliquots of lysates (40 μg) of A375 and M6 cells incubated for 24 h with MSC-CM were subjected to Western blotting. The primary antibodies were anti-uPAR (1:1000; mouse monoclonal antibody, Santa Cruz, Santa Cruz, California), which recognizes the full-length uPAR; anti-SNAIL1 (Biorbyt, Cambridge, UK), anti-α SMA (Sigma-Aldrich, St. Louis, Missouri), anti-N-Cadherin (Santa Cruz, Santa Cruz, California), anti-GAPDH (mAbcam, Cambridge, UK). After incubation with horseradish peroxidase-conjugated donkey anti-mouse or anti-rabbit or anti-goat IgG (1:10,000) for 1 h, immune complexes were detected with an enhanced chemiluminescence ECL detection system (GE Healthcare, Milano, Italy). The membranes were exposed to autoradiographic films for 1-10 min.
Total RNA preparation and reverse transcription were performed as reported [19] Amplification was performed with the default PCR setting: 40 cycles of 95°C for 15 s and of 60°C for 60 s using SYBR Green-based detection (GoTaq qPCR Master Mix; Promega, San Luis Obispo, California). Primer sequences (IDT, TemaRicerca, Bologna, Italy) are reported in Table 1 .
For immunofluorescence confocal microscopy, cells were grown on coverslips, fixed, and permeabilized according to routine methods. The anti-human primary antibodies used were anti-Vimentin (1:1000) (Sigma-Aldrich, St. Louis, Missouri), anti-E-cadherin (1:500), anti-N-cadherin (1:500), anti-TGFβ (1:500) (Santa Cruz, Santa Cruz, California), anti-NFkB (1:500) (GeneTex, Irvine, California). Secondary antibodies were anti-Rabbit IgG (whole molecule)-Cy3 conjugated (1:1000) (Sigma-Aldrich, St. Louis, Missouri), anti-Mouse IgG (whole molecule)-FITC conjugated. For nuclear staining, samples were incubated with 4,6-diamidino-2-phenylindole (10 μg/ml) [23] , for 15 min. In negative control slides, primary antibody was omitted. Coverslips were mounted and imaged on a Bio-Rad (Hercules, California) MRC 1024 ES confocal laser scanning microscope equipped for fluorescence measurements.
Invasion assay
Cells invasion was studied in Boyden chambers in which the upper and lower wells were separated by 8 μm pore-size polycarbonate filters coated with Matrigel (50 μg/filter; BD Biosciences, Franklin Lakes, New Jersey). Cells ( 15×10 3 ) were placed in the upper well and different CMs in the lower well. Invasion was performed for 6 h at 37°C-5 % CO 2 [24, 25] . In some experiments, invasion was performed in the presence of a MMP inhibitor Ilomastat (Millipore, Billerica, Massachusetts), to unpolymerized Matrigel solution.
SDS-PAGE zymography
For zymography, aliquots of media conditioned by tumor cells, either exposed to MSC-CM or not, were mixed with 4×(v/v) sample buffer (0.25 mol/l Tris-HCl, pH 6.8, 0.4 % SDS, 40 % glycerol and bromophenol blue), then loaded onto a 10 % SDS gel containing 1 mg/ml gelatin (Sigma-Aldrich, St. Louis, Missouri) and run under non-reducing conditions. Gels were washed in 2.5 % Triton X-100 for 30 min and then incubated overnight at 37°C in developing buffer (50 mmol/l Tris pH 8.0, 5 mmol/l CaCl 2 , 0.2 mol/l NaCl and 0.02 % Brij-35). Lysis areas in the gels were visualized by staining with Coomassie R-250 (0.5 % (wt/vol), followed by destaining [26] . uPAR downregulation with antisense oligodeoxynucleotide uPAR gene expression was inhibited using an 18-mer phosphorothioate aODN (ISIS Pharmaceuticals, Carlsbad Research Center, California) as described [24] , as a negative control, we used a degenerated oligodeoxynucleotide (dODN), which is a mixture of all possible combinations of bases that compose the aODN [27] .
In vivo experiments
All procedures involving animals were performed in accordance with national guidelines and approved by the ethical committee of Animal Welfare Office of Italian Work Ministry. ND1 immunodeficient mice (6-8 weeks old; Charles River, Lecco, Italy) were injected subcutaneously with 100 μl of PBS containing 1×10 6 melanoma cells alone or mixed with 0.5×10 6 MSCs (four animals/group). Tumor development 
was monitored at regular intervals by measuring tumor volume determined by the following formula: (L×W 2 )/2, where L and W are the length and width of tumor mass. To evaluate p17 effect on in vivo tumor growth, we injected melanoma cells and MSC into nude mice and, after 2 days, mice were randomly divided into 2 groups each with eight mice, one group was given p17.i.v., the other a control solution, on alternate days, for a total of 12 injections. Tumor growth was followed as reported above.
Statistical analysis
Results are expressed as means±SEM of 3 independent experiments performed in triplicate, and significant difference among experimental conditions was established at p<0.05 and performed by Student's t test.
Results
Correlation between uPAR and TGFβ/TGFβR system
Cancer progression and metastasis are related to the ability of cancer cells to degrade and to invade the extracellular matrix (ECM) and to their capacity to undergo EMT. Experimental and clinical evidences show a critical role of both the uPA/ uPAR system [28] [29] [30] and the TGFβ/TGFβR system [10, 11] in tumor progression. In this study, we first evaluated uPAR and TGFβ system in various melanoma cell lines. Quantitative real-time PCR revealed variable expression of uPAR and TGFβ system in different melanoma cells (Fig. 1) , and we found that high levels of TGFβ and TGFβRI and II corresponded with high levels of uPAR. To study the influence of MSCs in inducing EMT program and melanoma cell invasion, our further investigation was performed using two cell lines which expressed low levels (A375) and high levels (A375-M6, isolated in our laboratory from lung metastasis of A375 human melanoma cell lines, indicated as M6 throughout the text) of these molecular systems.
Medium conditioned by human MSCs promotes EMT program in melanoma cells
To evaluate the role of MSC-CM in cancer progression, we first examined some typical EMT parameters acquired by A375 (Fig. 2 ) melanoma cells exposed to MSC-CM. MSC-CM-treated melanoma cell exhibited a more elongated morphology with bipolar processes compared to the larger control cells, with flattened aspect (Fig. 2a) . RT-PCR analysis showed a significant increase of mesenchymal-associated genes such as N-cadherin, α-SMA and vimentin, a decrease of Ecadherin and an enhanced expression of E-cadherin transcriptional repressors such as SNAIL1 and SNAIL2 (Fig. 2b) . The enhanced expression of N-Cadherin, vimentin, and NF-kB as well as the decrease of E-cadherin was also confirmed by immunofluorescence confocal microscopy (Fig. 2c) . Western blot analysis further showed an increase of SNAIL1 and α-SMA transcription factors at protein level in MSC-CM-treated cells (Fig. 2d) .
Since matrix metalloproteinases (MMPs) activity drives cell invasiveness and represents an additional marker of EMT, we assessed the MMPs expression. RT-PCR analysis showed that MSC-CM increased the expression of MMP-9 compared to the level of untreated cells (Fig. 2e) , while MMP2 did not change (data not shown). The same results were obtained by using M6 melanoma cells ( Supplementary  Fig. S1 )
Then, we tested a key biological property related to EMT program, e.g., in vitro cell invasion and proliferation and in vivo growth. Using Matrigel invasion assay, we demonstrated that in the presence of MSC-CM, both A375 and M6 cell lines migrated more efficiently than untreated cells. This invasive property was MMP-dependent as was impaired by the presence of the MMPs inhibitor Ilomastat ( Supplementary  Fig S2a, S2b) . Moreover, we demonstrated that MSC-CM stimulates in vitro proliferation of melanoma cells ( Supplementary Fig S2c, S2d) .
MSCs promotes melanoma xenografts
The in vivo experiments showed that when MSCs were co-injected with melanoma cells into immunodeficient mice, they promote growth of tumors ( Supplementary  Fig S2e, S2f) ; no spontaneous metastasis development was observed in tumor-bearing animals either injected with MSC/melanoma cells or melanoma cells only (data not shown). The in vivo growth behavior in the absence or in the presence of MSCs greatly differed between M6 and A375 cells. After 18 days, tumor growth of M6 alone was higher (0.4± 0.15 cm 3 ) and faster than A375 (0.08±0.02 cm 3 ). In the presence of MSCs, tumor growth was strongly increased primarily after injection into mice of A375 cells compared to injection of M6 cells. Based on the stronger responsiveness of A375 melanoma cells, we decided to use this cell line to further investigate the role of MSCs in the melanoma tumor progression. uPAR and TGFβ/TGFβR expression in MSC-CM-treated melanoma cells
We next evaluated uPAR expression in A375 cells incubated with CM-MSC and demonstrated uPAR upregulation in the presence of CM-MSC (Fig. 3a) . Moreover, we evaluated the expression of TGFβ/TGFβ-receptors (TGFβRI, RII and RIII) in MSC-CM-treated melanoma cells. We found that mRNA for all three TGFβ receptors and of TGFβ were upregulated in the order of 2-3 times (Fig. 3b, c) . Also, TGFβ determination in supernatants from untreated cells and MSC-CM-treated cells indicates that MSC-CM increased TGFβ release by melanoma cells compared to TGFβ in the medium of control untreated A375 and of MSC (Fig. 3d) , seen by Western blotting analysis. TGFβ signaling in responding cells requires a complex mechanism involving TGFβRIII and the subsequent activation of the transmembrane Ser/Thr protein kinase receptors, type I and type II, which consequently phosphorylate and activate SMAD family genes. As shown in Fig. 3e , 60-min MSC-CM treatment induced phosphorylation of SMAD3 with the same efficacy of TGFβ. Of note, pSMAD3 level remained high up to 90 min when the effect of TGFβ began to decline. It is possible that TGFβ released by MSC might have a role in TGFβ/TGFβR upregulation in melanoma cell exposed to MSC-CM.
TGFβ as a putative regulator of EMT in melanoma cells exposed to MSC-CM
To investigate whether TGFβ plays a role in the promotion of melanoma EMT induced by MSC-CM, we impaired TGFβ activity both by silencing TGFβ in MSCs and by inhibiting the interaction between TGFβ and TGFβRIII.
First, we silenced TGFβ in MSCs by specific TGFβ-siRNA, which almost completely downregulated TGFβ mRNA level (Fig. 4a) . Then, we evaluated uPAR expression together with some typical parameters of EMT in A375 melanoma cells incubated with a medium obtained by TGFβ-silenced-MSC (siTGFβ-MSC). We demonstrated that incubation of A375 melanoma cells with siTGFβ-MSC-conditioned medium (si-TGFβ-MSC-CM) abrogates uPAR upregulation induced in melanoma cells by control MSC-CM (si-control- (Fig. 4b) . We also showed that A375 melanoma cells incubated with siTGFβ-MSC-CM decreased invasive property through Matrigel (Fig. 4c) and expressed lower level of N-cadherin (Fig. 4d) compared to A375 cells treated with si-control-MSC-CM. Moreover, A375 melanoma cells exposed to siTGFβ-MSC-CM showed a reduced expression of TGFβ and TGFβRIII (Fig. 4e, f) .
To confirm the key role exerted by TGFβ in MSCmediated EMT profile in melanoma cells, we tested the effects of a TGFβ-RIII inhibitor, the so-called peptide p17 (21) , which displays a high affinity for soluble TGFβ and a potent inhibitory effect on TGFβ binding to its receptor III. Peptide p17 suppressed upregulation of EMT markers, such as Ncadherin (Fig. 5a) , vimentin, and NF-kB (Fig. 5b) , in TGFβ1. Equal sample loading was confirmed by Ponceau S staining of the Western blot membrane. Histograms report band densitometry, assuming 1 as the reference value of control. e A375 were treated for the indicated time points with CM-MSC or TGFβ. Cell extracts were subjected to Western immunoblotting to detect the phosphorylation levels of SMAD3 compared to total SMAD2/3 Fig. 4 TGFβ1 produced by MSC mediates EMT in melanoma cells. a MSC cells were transfected with specific TGFβ1 siRNAs (si-TGFβ1) which significantly downregulated the gene. As control, no targeting siRNA (si-Control) was used. GAPDH used as reference gene. b uPAR mRNA levels were determined in A375 challenged for 24 h with CM collected from MSC transfected with control or specific si-TGFβ1. c Cell invasion of A375 treated with CM from MSC transfected with (siControl) or with si-TGFβ1. d N-cadherin expression levels. e Real-time PCR analysis was performed in A375 treated as described in (a, b) to evaluate the expression levels of TGFβ-RIII. Results are expressed as fold change according to 2-ΔΔCT method. The numbers 1, 2, and 3 refer to the legend in panel a melanoma cells exposed to MSC-CM. Moreover, we observed a strong inhibition of MSC-CM-dependent invasion (Fig. 5c ) and MMP-9 expression (Fig. 5d) . i.v administration of peptide p17 in tumor-bearing mice injected with melanoma cells together with MSCs led to a significant decrease of tumor growth, justifying the role exerted by TGFβ in MSC/ melanoma cell crosstalk (Fig. 5e) .
Our data indicate that TGFβ represents a crucial effector of EMT program in melanoma cells exposed to MSC-CM. uPAR mediates TGFβ-dependent EMT of melanoma cells exposed to MSC-CM On the basis of our results, with the aim to study the relationship between TGFβ and uPAR, we inhibited uPAR expression by using a specific uPAR antisense oligodeoxyribonucleotides (uPAR aODN) added in culture medium. In all experiments described in Fig. 6 , the term Bcontrol cells^refers to cells cultured in the presence of dODN, which does not affect uPAR expression and its biological effects. In the presence of uPAR aODN, we observed a drastic reduction of uPAR expression in control cells as well as in melanoma cells treated with MSC-CM or with exogenous TGFβ (Fig. 6a) . On the basis of these results, we evaluated whether the downregulation of uPAR was also able to revert EMT induced by MSC-CM or by exogenous TGFβ. We demonstrated that uPAR aODN inhibited EMT markers N-cadherin and SNAI L1 both in A375 melanoma cells incubated with MSC-CM or treated with exogenous TGFβ (Fig. 6b) . Moreover, uPAR aODN exerted a same inhibitory effect on the invasive property of A375 melanoma cells conditioned by MSC-CM or treated with exogenous TGFβ (Fig. 6c) . These results strongly indicate that uPAR mediates TGFβ-dependent EMT of melanoma cells exposed to MSC-CM.
Discussion
Tumor growth and progression are dependent not only on malignant cells but also on a favorable tumor microenvironment formed by stromal fibroblasts, immune cells, endothelial cells, and MSCs.
Here, we have approached the role of human MSCs in melanoma progression and, in particular, in EMT program acquisition. We observed that melanoma cells exposed to MSC-CM acquired a mesenchymal morphology, expressed specific EMT markers, such as N-cadherin, vimentin, α-SMA as well as SNAIL2 and SNAIL1 transcription factors and showed a reduction of E-cadherin. The acquired mesenchymal phenotype was also characterized by an increase in vitro proliferation and MMP-dependent invasiveness. Moreover, in vivo injection of melanoma cells together with MSCs induced an increased growth rate of tumors, as compared to injection of melanoma cells alone. No spontaneous metastases were observed in target organs, possibly due to the high rate of tumor growth limiting duration of the experiments; for ethical reasons, suffering tumor-bearing mice were euthanized. EMT is a complex scenario of changes elicited with different agonists and characterized by low proliferation, mesenchymal markers, resistance to apoptosis, motility, and in certain circumstances stemness. EMT is not a permanent phenotype, but MET occurs and tumor cells regain an epithelial morphology and a high proliferation rate. We speculate that in our conditions, A375 cells acquired a Bhybrid^phenotype characterized by high proliferative activity in the presence of mesenchymal markers. This might be related to crosstalk between TGFβ signaling and NF-kB pathway as suggested by Freudisperger C. et al. [31] We also demonstrated that incubation of A375 melanoma cells with MSC-CM upregulated TGFβ and the receptors TGFβ-RI,II,III and enhanced TGFβ signaling. Silencing TGFβ in MSCs abrogated in melanoma cells upregulation of N-cadherin, invasiveness, TGFβ, and TGFβRIII expression. Moreover, the TGFβRIII inhibitor peptide p17 downregulated EMT marker expression and reduced tumor growth of melanoma cells injected with MSC. These data suggest TGFβ as a driver of EMT in melanoma cells exposed to MSC-CM. Indeed, TGFβ plays a crucial role in progression and metastatic diffusion of many tumors, including melanoma, by changing from tumor suppressor in the premalignant stages to prooncogene at later stages of the disease. TGFβ-dependent acquisition malignancy-related properties are connoted by loss of TGFβ-dependent growth inhibition, apoptosis and genomic stability, and by increased expression/ activation of TGFβ/TGFβR system [32] . Tumor cells themselves may over-produce active TGFβ, as well as proteases that, besides activating TGFβ, also degrade ECM, with a consequent release of stored TGFβ. Moreover, TGFβ acts as a potent promoter of EMT via activation of canonical Smad and non-canonical Smad-independent pathways thus leading to changes in cellular morphology from epithelial to mesenchymal phenotype [33, 34] . Indeed, Schlegel demonstrates that TGFβ-induced EMT-like profile in melanoma cells is marked by the downregulation of melanocyte differentiation markers, such as MITF, and the upregulation of mesenchymal markers, such as N-cadherin, and an increase in melanoma cell migration and cell invasion [35] . Furthermore, Hoek reports that TGFβ promotes metastatic phenotype in melanoma cells through upregulation of genes expressing vasculogenic/ extracellular matrix remodeling factors and Wnt signal inhibitor [36] .
In some circumstances, such as breast and colorectal cancers, induction of EMT by MSC required cell-to-cell contact and surface expression of TGFβ on MSCs is instrumental for tumor cells undergoing EMT [5] . Furthermore, reports indicate that tumor-derived TGFβ plays a role in attracting MSCs, [37] implying an auto-maintained mechanism, involving tumor cells/MSC interactions.
Tumor progression is also characterized by increased expression of uPA/uPAR system, and many data indicate a regulative role of TGFβ on uPA/uPAR system in endothelial cells [13, 22] and in many cancer cells, as reviewed by Santibanez [14] . uPA/uPAR system is actually considered the main system involved in tumor invasion and metastasis, as well as in tumor angiogenesis [15] . Endogenous levels of uPA and uPAR increase with disease progression, correlate with poor prognosis and outcome in patients, and therefore can be considered a good target for anti-tumoral therapy [38] . uPAR is critical in invasive properties of malignant cells since it is involved both in ECM degradation and in cell adhesion through a Bgrip-and-go^mechanism [39] . We have previously shown that uPA-uPAR interaction induces endothelial cell chemotaxis [40] and stimulates angiogenesis in the rabbit cornea [41] . Inhibition of uPAR expression with a specific uPAR antisense oligonucleotide (uPAR aODN) inhibits tumor cell invasion, angiogenesis and metastasis [23, 24] , and MMPs [42] . Recently, we demonstrated that uPAR controls plasticity of cancer cell as it is involved in converting migration style from the Bpath generating^mesenchymal to the Bpath finding^amoeboid one, in prostate cancer and in melanoma [23] . Also, uPAR induce EMT in cancer cells [16] and is involved in hypoxia-induced EMT [17] .
These finding induced us to check a correlation between levels of TGFβ and uPAR in different melanoma cell lines, and we verified that cell lines expressing high level of TGFβ system also expressed high level uPAR. These results led us to investigate whether uPAR might have a role in TGFβ-induced EMT by MSC-CM. We found that TGFβ-siRNA abrogates uPAR in melanoma cells treated with MSC-CM. Moreover, using uPAR aODN, we proved that uPAR downregulation inhibited expression of N-cadherin and SNAIL1 transcription factor as well as the invasive properties in melanoma cells either stimulated with MSC-CM or with exogenous TGFβ. Thus, uPAR may work together with TGFβ in stimulating EMT in melanoma cells grown in MSC-CM.
These results have shown the interplay between uPAR and TGFβ as an emerging crucial factor in cancer progression and metastasis. This crosstalk could be an attractive target for cancer therapy. By inhibiting TGFβ and uPAR, it is possible to abrogate the positive and dangerous interaction between cancer cells and MSCs of tumor environment. Such a combined therapy can open a new therapeutically way for melanomabearing patients.
